Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market

TM Editors Note: This article discusses one or more penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

Not that many years ago, our healthcare system wasn’t strongly focused on head injuries, or more properly, Traumatic Brain Injury (TBI).

Unless a patient exhibited overt and persistent neurological symptoms, the injury was typically written off as “a knock on the head” (mild concussion), and the patient was simply advised to have a few days rest. Any medication provided was primarily for pain relief.

Today, Traumatic Brain Injury has leapt to the forefront in our healthcare system. Through improved diagnostics (and simply greater attentiveness), medical science now understands that TBI can lead to a host of serious long-term effects.

Huge medical problem/major treatment market

Now that it is diagnosed more aggressively, the prevalence of TBIs is sobering. A recent Psychedelic Stock Watch article laid out the numbers.

TBI in the United States

  • An estimated 2.8 million people sustain a TBI annually.1 Of them:
    • 50,000 die,
    • 282,000 are hospitalized, and
    • 2.5 million, nearly 90%, are treated and released from an emergency department.
  • TBI is a contributing factor to a third (30%) of all injury-related deaths in the United States.1
  • Every day, 153 people in the United States die from injuries that include TBI.1
  • Most TBIs that occur each year are mild, commonly called concussions.2
  • Direct medical costs and indirect costs of TBI, such as lost productivity, totaled an estimated $60 billion in the United States in 2000.3

With nearly 1% of the population sustaining a TBI each year, the odds are somewhere around 50/50 that a person will sustain at least one TBI over the course of their life.

Beyond the immediate deaths and hospitalizations, TBI can leave sufferers with (potentially) a host of long-term symptoms, including: headaches and migraines, dizziness, sensitivity to light and sound, visual difficulties, fatigue, and seizures/post-traumatic epilepsy.

This is not only a major treatment crisis for the healthcare sector, it is a major opportunity for investors.

1 2 3 4
View single page >> |

Disclaimer: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
James Hunter 3 weeks ago Member's comment

Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."

James Hunter 3 weeks ago Member's comment

Bright future for psychedelics TBI R&D

With a half-dozen companies in the psychedelics industry already with announced plans for TBI-related research, some investors may see this R&D niche as crowded.

But with a huge treatment population and an equally huge treatment market to target (estimated to reach $182 billion by 2027), there are more than enough revenue dollars on the table for second- and third-place finishers in this derby to be well-rewarded by the market.